BioMarin announces positive pivotal data for Palynziq (pegvaliase-pqpz) in adolescents with phenylketonuria
BioMarin Pharmaceutical Inc. announced that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in adolescents… read more.
